A new U.S. study found Anoro Elipta to be better than Bevespi Aerosphere or Stiolto Respimat at lowering the risk of disease flares in COPD.

Researchers have found a promising treatment breakthrough for chronic obstructive pulmonary disease (COPD) that avoids many of the drawbacks of current drugs, and it has come from an unexpected place.

Chronic obstructive pulmonary disease (COPD) remains a substantial contributor to morbidity and mortality in the United States with an estimated 3.8% age-adjusted prevalence and 141,733 COPD deaths ...

While COPD (chronic obstructive pulmonary disease) symptoms may start out as mild to moderate — with episodes of difficulty breathing that come and go — over time, COPD tends to get worse, and many ...

In May 2025, the FDA approved mepolizumab (Nucala) as a treatment for chronic obstructive pulmonary disease (COPD). Before any drug gets near a pharmacy shelf, it starts with years of basic science ...

GSK is heading into the weekend with a win for its respiratory blockbuster Nucala—but for now, the details are slim. On Friday, GSK said that its IL-5 antibody Nucala plus inhaled maintenance therapy ...

Asthma and COPD share similar breathing symptoms, often leading to confusion and misdiagnosis. Know key differences, risks of ...

Please provide your email address to receive an email when new articles are posted on . Smoking abstinence during week 9 to week 12 among adults with COPD was 19.1% with 12-cytisinicline vs. 4.3% with ...